Close

Novo Nordisk (NVO) Receives FDA Approval for Xultophy 100/3.6 NDA in T2D-Related Glycaemic Control

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/24/2024

1. TSLA
2. ENPH
3. TXN
4. V
5. SPOT
6. KMB
7. FI
8. MSCI
9. STX
10. MSFT


Go back to Novo Nordisk (NVO) Receives FDA Approval for Xultophy 100/3.6 NDA in T2D-Related Glycaemic Control
NOVO-NORDISK A/S (NYSE: NVO) Delayed: 128.64 --0 (-0%)
Previous Close $128.64    52 Week High $59.00 
Open $128.64    52 Week Low $32.80 
Day High $128.64    P/E N/A 
Day Low $128.64    EPS $0.00 
Volume 50,577